Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
about
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaA critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsNRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literatureClinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Second malignancies after multiple myeloma: from 1960s to 2010s.Myelodysplastic syndromes, version 2.2015Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Molecular pathophysiology of myelodysplastic syndromes.Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.Unraveling the molecular pathophysiology of myelodysplastic syndromes.Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.Stem and progenitor cell alterations in myelodysplastic syndromes.Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).Differential expression of ribosomal proteins in myelodysplastic syndromes.Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
P2860
Q33695954-70212733-E0AD-43F3-9130-F3963B866F97Q33796552-A0BFE974-F1BF-404D-8FF2-4E938372F624Q34220013-FD7BAFA8-E482-4408-AD67-9996C5DEF614Q34398397-49F0D0CD-2165-46C1-A574-8386E7BD2197Q34740986-E9D0E31A-D875-4E47-93BA-30314D468C88Q34766950-76C54CA0-DE11-4A7D-8C45-7C9A0A432EE1Q35082495-4C3E5F82-D354-47DF-95CD-FF8AAE2A32D4Q35891594-37BFD174-4B37-4987-A4F1-F82D1B698D58Q36416338-380CEFDB-B471-46C1-8F2F-997D83F9CDEDQ36417421-7142BA83-B6CD-46BA-A984-CFB99A88457CQ36445968-76A69907-F881-4952-96B3-A071E92B6573Q36832931-247FA2BF-6765-42F4-BB47-9C5E20C327C1Q37671806-8DDCEF68-95ED-4B17-8C82-5EDAC7FA4B1FQ37799831-CD7E353F-AF55-46BE-A44A-DDEFACE190DDQ38074017-C9343D7F-AC3D-46D0-B15C-4618E24B6122Q38122703-210992D8-9F04-466A-AC21-24979BBE743CQ38177771-1A374173-A47F-46B9-951B-E4F36DFBC54EQ38761791-E21542D3-403E-4725-B7C6-430853047775Q38880077-A967A293-02C5-4D27-92A6-05FAC8002AE3Q38905610-2BAC9139-0459-4505-97C0-39FE69FC3A5EQ39013004-FD4C2B81-D094-4ED9-BCF4-EC412B786120Q39155501-5E17E8F4-056C-4E7D-A3B6-FF118783D4CFQ39811365-D95B3959-E5CC-4EC3-85A7-205C92BEF655Q41156034-00705BE5-13DF-4486-9E33-688EF1FBD070Q42285087-83736A33-B0C1-4FEF-9EB5-895CC4FA251CQ42586752-1D103B3D-23B4-4BA5-BD0D-4F12D500F703Q42638915-619A6AD8-5702-427C-A59C-B1AF5AB52776Q42879201-15B101F0-54EF-4010-BB8E-6781E3F38DB5Q45155324-A040BE8C-0738-4420-BE39-D4F1D443ADA6Q47548041-C0A8EAC3-F7AA-4B8F-886D-5204E12AB1E0Q48102067-13941705-7F99-412A-B754-3660B18875F9Q49472515-2B8BBBED-217D-4F0D-B7F5-7FE975747611Q52852892-1BE195D3-F231-4B63-8712-8485B146A7D4Q52914167-6FED5E4B-9D46-4B93-9F7C-B1733528EF1DQ54594035-58DB5623-9FA7-490B-B89C-27361923475B
P2860
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clonal heterogeneity in the 5q ...... expand at disease progression.
@en
Clonal heterogeneity in the 5q ...... expand at disease progression.
@nl
type
label
Clonal heterogeneity in the 5q ...... expand at disease progression.
@en
Clonal heterogeneity in the 5q ...... expand at disease progression.
@nl
prefLabel
Clonal heterogeneity in the 5q ...... expand at disease progression.
@en
Clonal heterogeneity in the 5q ...... expand at disease progression.
@nl
P2093
P2860
P50
P1433
P1476
Clonal heterogeneity in the 5q ...... expand at disease progression.
@en
P2093
Anna Porwit
Eva Hellström-Lindberg
Gudrun Göhring
James S Wainscoat
Leonie Saft
Martin Jädersten
P2860
P304
P356
10.3324/HAEMATOL.2009.011528
P577
2009-10-01T00:00:00Z